Cargando…
Designing Nanoconjugates to Effectively Target Pancreatic Cancer Cells In Vitro and In Vivo
BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer related deaths in America. Monoclonal antibodies are a viable treatment option for inhibiting cancer growth. Tumor specific drug delivery could be achieved utilizing these monoclonal antibodies as targeting agents. This type of desi...
Autores principales: | Khan, Jameel Ahmad, Kudgus, Rachel A., Szabolcs, Annamaria, Dutta, Shamit, Wang, Enfeng, Cao, Sheng, Curran, Geoffry L., Shah, Vijay, Curley, Steven, Mukhopadhyay, Debabrata, Robertson, J. David, Bhattacharya, Resham, Mukherjee, Priyabrata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124468/ https://www.ncbi.nlm.nih.gov/pubmed/21738572 http://dx.doi.org/10.1371/journal.pone.0020347 |
Ejemplares similares
-
Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics
por: Kudgus, Rachel A., et al.
Publicado: (2013) -
Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*
por: Bhattacharya, Resham, et al.
Publicado: (2008) -
The neurotransmitter dopamine modulates vascular permeability in the endothelium
por: Bhattacharya, Resham, et al.
Publicado: (2008) -
Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer
por: Madamsetty, Vijay Sagar, et al.
Publicado: (2020) -
VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma
por: Sinha, Sutapa, et al.
Publicado: (2010)